<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4209">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052127</url>
  </required_header>
  <id_info>
    <org_study_id>AU-011-101</org_study_id>
    <nct_id>NCT03052127</nct_id>
  </id_info>
  <brief_title>Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma</brief_title>
  <official_title>A Phase 1B Open-Label, Single Ascending Dose Clinical Trial Designed to Evaluate the Safety of Two Dose Levels of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aura Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aura Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety, immunogenicity and preliminary efficacy of a
      single treatment of one of two dose levels of Light-activated AU-011 for the treatment of
      subjects with primary choroidal melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1B open-label, single ascending dose clinical trial designed to evaluate the
      safety of two dose levels of Light-activated AU-011 for the treatment of subjects with small
      to medium primary choroidal melanoma.

      Throughout the study, subjects will be monitored through medical and ophthalmic assessments.
      Subjects will be followed for a total of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Light-activated AU-011</measure>
    <time_frame>Informed consent through 2 years</time_frame>
    <description>Adverse events will be summarized by presenting the number and percentage of patients having any adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Screening to various time points through Week 52</time_frame>
    <description>Anti-Drug Antibody analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy</measure>
    <time_frame>Change from baseline at 3 months following treatment</time_frame>
    <description>Tumor size measured by ultrasonography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Ocular Melanoma</condition>
  <condition>Choroidal Melanoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Light-activated AU-011</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Light-activated AU-011</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Light-activated AU-011</intervention_name>
    <description>Study treatment</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of uveal melanoma

        Exclusion Criteria:

          -  Have known contraindications or sensitivities to the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis O'Shaughnessy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aura Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rochelle M Summerfelt, MS</last_name>
    <email>rsummerfelt@aurabiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denis O'Shaughnessy, PhD</last_name>
    <email>denis@aurabiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>February 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveal melanoma</keyword>
  <keyword>Eye cancer</keyword>
  <keyword>Ocular melanoma</keyword>
  <keyword>Choroidal melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
